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BASIC RESEARCH
Intragraft interleukin 2 mRNA expression during acute
cellular rejection and left ventricular total wall thickness
after heart transplantation
H A de Groot-Kruseman, C C Baan, E M Hagman, W M Mol, H G Niesters, A P Maat,
P E Zondervan, W Weimar, A H Balk
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Objective: To assess whether diastolic graft function is influenced by intragraft interleukin 2 (IL-2) mes-
senger RNA (mRNA) expression in rejecting cardiac allografts.
Design: 16 recipients of cardiac allografts were monitored during the first three months after
transplantation. The presence of IL-2 mRNA in endomyocardial biopsies (n = 123) was measured by
reverse transcriptase polymerase chain reaction. To determine heart function, concurrent M mode and
two dimensional Doppler echocardiograms were analysed.
Results: Histological signs of acute rejection (International Society for Heart and Lung Transplantation
(ISHLT) rejection grade > 2) were strongly associated with IL-2 mRNA expression (IL-2 mRNA was
present in 12 of 20 endomyocardial biopsies (60%) with acute rejection and in 24 of 103 endomyo-
cardial biopsies (23%) without acute rejection, p = 0.002). No significant relation was found between
either histology or IL-2 mRNA expression alone and the studied echocardiographic parameters. How-
ever, stratification of the echocardiographic data into those of patients with and those without acute
rejection showed that during acute rejection IL-2 mRNA expression was significantly associated with
increased left ventricular total wall thickness (mean change in total wall thickness was +0.22 cm in
patients with IL-2 mRNA expression versus −0.18 cm in patients without IL-2 mRNA expression,
p = 0.048).
Conclusions: An increase in left ventricular total wall thickness precedes IL-2 positive acute rejection
after heart transplantation. Thus, cardiac allograft rejection accompanied by intragraft IL-2 mRNA
expression may be indicative of more severe rejection episodes.
Reversible diastolic dysfunction of cardiac allografts in thefirst postoperative months has been reported to correlatewith reduced long term survival.1 This diastolic dysfunc-
tion can be the result of acute rejection, a major complication
shortly after transplantation.2 However, not all histologically
proven acute rejection episodes result in changes of diastolic
function parameters. The underlying mechanism of the
difference between acute rejection episodes with and those
without impaired heart function is unknown but may involve
the local or systemic release of cytokines.2
Acute cellular rejection is morphologically characterised by
the presence of a mononuclear cell infiltrate and signs of
myocyte damage on endomyocardial biopsy (EMB).3 The
combination of infiltrated immune competent cells with
interstitial and perivascular oedema, vascular leakage of
fibrin, and in the more severe cases diffuse myocyte necrosis
can result in stiffness of the myocardium.4 Consequently, the
acute rejection process may change left ventricular wall
dimensions and left ventricular filling parameters, reflecting
the loss of diastolic heart function. Previously reported
echocardiographic changes related to acute cellular rejection
include increased left ventricular total wall thickness,
increased peak early mitral flow velocity (E), decreased decel-
eration time, and shortened isovolumetric relaxation
period.5 6 Alternatively, during vascular (humoral) rejection,
cells of the microvasculature instead of myocytes may be the
target of tissue injury, which has been associated with
increased left ventricular mass and depressed myocyte
function.4 7
In addition to cell infiltration and tissue damage, local pro-
duction of cytokines (low molecular weight regulatory
proteins) during rejection may also influence myocardial
function.8 9 One of the crucial cytokines in the modulation of
the alloimmune response is interleukin (IL) 2, which
enhances the proliferation and differentiation of specific T
lymphocytes directed against the allograft.10 11 In non-
transplant settings, IL-2 has been shown to cause dysfunction
of the heart both in experimental and in clinical studies.12 13 A
dose dependent negative inotropic effect of IL-2 was observed
in isolated hamster papillary muscle preparations.12 Moreover,
intravenous administration of IL-2 in patients with cancer
causes cardiovascular side effects including decreased ejection
fraction, decreased blood pressure, increased heart rate, and
fluid retention.13 Therefore, we speculate that after transplan-
tation the local presence of IL-2 may be related to allograft
dysfunction by reflecting the severity of the immune response
against the allograft and by its direct negative inotropic effect
on the myocardium. To determine whether local IL-2
expression during histological rejection indeed affects diasto-
lic graft function, we monitored serially sampled EMB for the
presence of IL-2 messenger RNA (mRNA) expression and for
histological signs of acute rejection during the first three
months after heart transplantation. These findings were ana-
lysed in relation to echocardiographic changes in wall dimen-
sions and diastolic flow parameters.
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METHODS
Patients
We studied 16 consecutive heart transplant recipients who
were operated upon between November 1997 and October
1998. Table 1 summarises the demographic data of these
patients. Maintenance immunosuppressive therapy consisted
of ciclosporin A and low dose steroids. Serial EMB and
echocardiograms during the first three months after trans-
plantation were studied. Surveillance biopsies during this
period were taken weekly during the first six weeks and
biweekly during the following eight weeks. During routine
biopsies two additional samples were harvested for cytokine
studies after informed consent of the patients. One patient has
been excluded from analysis because of the poor quality of
serial echocardiograms, leaving 15 patients in the study group.
In total, 123 biopsies with concurrent echocardiograms (on
average eight time points per patient) were available for
analysis. Acute rejection was diagnosed by histological assess-
ment of myocardial biopsies and graded according to the
guidelines of the International Society for Heart and Lung
Transplantation (ISHLT).3 Patients with ISHLT rejection grade
> 2 were considered to have an acute rejection (AR+) and
received additional immunosuppressive treatment.
Echocardiography
Echocardiographic examination was completed within four
hours of biopsy sampling using a Hewlett Packard Sonos 500
or 5500 ultrasonograph (Hewlett Packard, Palo Alta, Califor-
nia, USA) with a 3.75 MHz transducer. All recordings were
made and analysed by a single investigator without knowl-
edge of the results of EMB. M mode recordings for
measurement of left ventricular wall dimensions were
obtained from the parasternal long axis view in combination
with an ECG, phonocardiogram, and respiratory tracing. For
two dimensional Doppler echocardiography the transducer
was positioned at the cardiac apex for a standard apical four
chamber view. Mitral flow velocities were recorded within the
valve orifice near the leaflet tips with the sample volume
placed parallel to the ventricular inflow tract.
Offline, M mode, and two dimensional Doppler echocardio-
grams were analysed using a software program developed in
our laboratory with a hand held digitiser connected to a digi-
tising tablet (Summa Sketch Plus, Summagraphics, Seymour,
Connecticut, USA) interfaced with a personal computer. ForM
mode echocardiogram analysis, means of five consecutive end
expiratory beats were calculated. M mode echocardiograms
were analysed for end diastolic posterior left ventricular wall
thickness and end diastolic interventricular septum thickness.
Left ventricular total wall thickness was calculated by adding
end diastolic posterior wall thickness and end diastolic inter-
ventricular septum thickness. Two dimensional Doppler
echocardiograms were analysed for the following diastolic
function parameters: E, peak atrial mitral flow velocity (A),
E/A ratio, deceleration time of E, and isovolumetric relaxation
period. For Doppler echocardiogram analysis, means of 10
consecutive end expiratory beats were calculated. Beats that
were distorted by the recipient atrial contraction were not
analysed with respect to deceleration time. The transmitral
filling pattern was classified as “summation filling”when only
one peak occurred in diastole after the P wave of the succeed-
ing beat. In such recordings, E and A waves could not be rec-
ognised and consequently the parameters E, A, E/A ratio, and
deceleration time were not measured.
IL-2 mRNA detection
Reverse transcriptase polymerase chain reaction (PCR) was
used for detection of IL-2 mRNA expression. Therefore, total
RNA was extracted from snap frozen EMB, and subsequently
complementary DNA (cDNA) was synthesised with random
primers as described previously in detail.14 Aliquots of cDNA
(representing 1/20 EMB) were directly used for PCR amplifi-
cation using sequence specific primers for IL-2 (sense: 5′-ATG
TAC AGG ATG CAA CTC CTG TCT T-3′; antisense: 5′-GTC AGT
GTT GAG ATG ATG CTT TGA C-3′). Sample cDNA (5 µl) was
added to a 95 µl PCR mixture containing 10 mM Tris-HCl pH
8.3, 50 mM KCl, 1.5 mM MgCl2, 0.2 mM each of deoxy-ATP,
deoxy-CTP, deoxy-TTP, and deoxy-GTP, 2 U Taq polymerase
(Applied Biosystems, Norwalk, Connecticut, USA) and over-
laid with 100 µl mineral oil (Sigma, St Louis, Missouri, USA)
before PCR in a DNA thermal cycler model 480 (Applied Bio-
systems) under the following conditions. After a 5 minute
94°C denaturation step, samples underwent 40 cycles of dena-
turation for 1 minute at 94°C, 2 minutes’ annealing at 60°C,
and 3 minutes’ extension at 72°C. The last cycle was extended
to 7 minutes at 72°C.
Positive control samples were produced by mRNA extrac-
tion and cDNA synthesis from 106 random human spleen cells
stimulated with 1% phytohaemagglutin M (Difco, Detroit,
Michigan,USA) for 24 hours at 37°C.Negative control samples
consisted of diethyl pyrocarbonate treated H2O as a no
template reaction. In all samples, constitutively expressed
glyceraldehyde 3-phosphate dehydrogenase mRNA was am-
plified in a separate PCR (3-phosphate dehydrogenase
Table 1 Demographics of the studied patients and the numbers of endomyocardial biopsies (EMB) positive for acute
rejection (AR+) and interleukin 2 (IL-2) messenger RNA (mRNA) expression (IL-2+)
Patient Age (years) Sex
Primary
disease EMB AR+ EMB IL-2+ EMB AR+/IL-2+ AR−/IL-2+
1 20 F CMP 8 2 1 1 0
2 52 M IHD 9 0 5 0 5
3 60 M IHD Excluded from the study due to poor echocardiographic quality
4 48 M IHD 9 2 4 2 2
5 58 M CMP 8 1 1 1 0
6 51 M CMP 8 1 2 1 1
7 56 F CMP 7 1 3 1 2
8 58 M IHD 9 2 3 2 1
9 53 F CMP 8 4 2 0 2
10 50 M IHD 7 1 1 0 1
11 16 F CMP 6 2 2 2 0
12 54 M IHD 8 2 4 1 3
13 43 M CMP 8 2 3 1 2
14 55 M IHD 9 0 2 0 2
15 58 M IHD 9 0 2 0 2
16 52 M IHD 10 0 1 0 1
Total 123 20 36 12 24
CMP, cardiomyopathy; F, female; IHD, ischaemic heart disease; M, male.
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primers, sense: 5′-GGT GAA GGT CGG AGT CAA CG-3′; anti-
sense: 5′-CAA AGT TGT CAT GGA TGA CC-3′) to confirm suc-
cessful mRNA extraction and cDNA transcription. EMB that
were negative for 3-phosphate dehydrogenase mRNA expres-
sion were excluded from further analysis.
The presence of IL-2 mRNA on an agarose gel was visually
assessed as present (IL-2 positive) or not present (IL-2 nega-
tive) and confirmed by Southern blot hybridisation. Therefore,
products on the agarose gel were transferred to a Hybond-N+
membrane (Amersham, Buckinghamshire, UK) by electrob-
lotting and subsequently hybridised with a γ32P labelled
specific probe for IL-2 (5′-TTC TTC TAG ACA CTG AAG ATG
TTT CAG TTC-3′), which is located across the splice site.
Hybridisation was detected by autoradiography and indicated
the presence of IL-2 mRNA expression in the original biopsy.
Statistical analysis
Differences in mean echocardiographic parameters between
EMB with and those without either histologically proven
acute rejection or IL-2 mRNA expression were analysed by
Student’s t test. Associations between IL-2 mRNA expression
and acute rejection, as well as changes in wall dimension
between the first measurement and the first acute rejection
biopsy with or without IL-2 mRNA expression, were
calculated by Fisher’s exact test in a cross table. Associations
with p < 0.05 were considered significant.
RESULTS
Acute rejection
In 4 of 16 patients no histological signs of acute rejection were
observed during the first three months after transplantation.
These non-rejectors served as the control group. One of the
rejectors (patients with at least one AR+ biopsy) was
excluded from analysis because of poor echocardiographic
quality. Overall, 20 of 123 EMB were positive for acute
rejection (16%). Table 1 shows the total number of AR+ biop-
sies with acute rejection during follow up of the patients.
IL-2 mRNA expression in relation to rejection
Serial measurements of IL-2 mRNA expression showed that
every patient in the rejector group and in the non-rejector-
group had at least one IL-2 positive EMB during the first three
months after transplantation. Overall, IL-2 mRNA expression
was detected in 36 of 123 EMB (29%). Table 1 summarises the
number of IL-2 positive EMB in the presence (AR+) or
absence of acute rejection (AR−) during follow up. IL-2 mRNA
expression was strongly associated with histological signs of
acute rejection requiring treatment. IL-2 mRNA was present
in 12 of 20 EMB (60%) with histological signs of acute rejec-
tion and in 24 of 103 EMB (23%) without these histological
characteristics (p = 0.002, Fisher’s exact test; table 2).
Diastolic function in relation to rejection and IL-2
mRNA expression
A large individual variation was observed in the echocardio-
graphic measurements. No differences in the echocardio-
graphic variables were observed at the group level between
AR+ and AR− biopsies (table 3), between biopsies with or
without IL-2 mRNA expression (table 3), or between the sub-
divided AR+ and AR− samples in biopsies with or without
IL-2 mRNA expression (table 4).
In the search for changes over time, differences in the
echocardiographic parameters were calculated between the
first postoperative measurement and the time of the first acute
rejection or IL-2 mRNA expression. In this way, each patient
served as his or her own control. Because the first echocardio-
graphic measurement was used as the baseline, patients with
acute rejection or IL-2 mRNA expression at the time of their
first measurement (n = 2 and n = 4, respectively) were
excluded from this specific analysis. Neither histological signs
of acute rejection nor IL-2 mRNA expression alone was asso-
ciated with individual changes over time in any of the studied
echocardiographic parameters. However, by relating intragraft
IL-2 positivity to echocardiographic changes over time after
stratifying the data into AR+ and AR− time points, we found
that IL-2 mRNA expression during the first acute rejection
was significantly associated with increased left ventricular
total wall thickness between the first postoperative measure-
ment and the first acute rejection episode (fig 1). In five of six
patients with IL-2 mRNA expression during their first acute
rejection, increased total wall thickness had preceded that
rejection episode (mean (SD) change between the first
postoperative measurement and the measurement during the
first acute rejection episode was +0.22 (0.12) cm). In all
patients without IL-2 mRNA expression during their first
acute rejection, total wall thickness decreased (mean (SD)
−0.18 (0.12) cm; p = 0.048, Fisher’s exact test; fig 1). In all
non-rejecting control patients, total wall thickness decreased
during their first IL-2 positive EMB with respect to the first
postoperative measurement (mean (SD) −0.30 (0.31) cm).
The only patient in whom total wall thickness had decreased
preceding an IL-2 positive acute rejection episode had an
exceptionally high total wall thickness of 2.68 cm during the
first postoperative measurement, which may be attributable to
the known history of hypertension of the donor. During the
IL-2 positive rejection episode, the total wall thickness of this
patient decreased to 2.32 cm, which is still relatively high.
Table 2 Cross table of the number of
biopsies negative and positive for acute
rejection (AR−; AR+) and IL-2 mRNA
expression (IL-2−; IL-2+)
AR− AR+ Total
IL-2− 79 8 87
IL-2+ 24 12 36
Total 103 20 123
Table 3 Echocardiographic parameters at the time of EMB with (AR+) and without (AR−) acute rejection, and with
(IL-2+) and without (IL-2−) IL-2 mRNA expression
AR− AR+ p Value IL-2− IL-2+ p Value
TWT (cm) 2.12 (0.30) 2.12 (0.26) 1.00 2.15 (0.30) 2.12 (0.34) 0.65
E (m/s) 0.82 (0.22) 0.81 (0.23) 0.85 0.81 (0.20) 0.85 (0.24) 0.35
E/A ratio 2.20 (0.70) 2.00 (0.78) 0.32 2.16 (0.74) 2.08 (0.61) 0.63
DET (ms) 161.9 (36.6) 151.3 (29.8) 0.28 159.6 (30.2) 160.6 (45.0) 0.90
IRP (ms) 64.83 (19.92) 69.4 (20.29) 0.41 64.41 (21.14) 66.73 (20.20) 0.63
Data are mean (SD).
A, peak atrial mitral flow velocity; DET, deceleration time of peak early mitral flow velocity; E, peak early mitral flow velocity; IRP,: isovolumetric relaxation
period; TWT, left ventricular total wall thickness.
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DISCUSSION
Diastolic function in relation to rejection
Numerous investigators have explored the clinical use of
echocardiography to replace invasive EMB sampling for the
diagnosis of acute rejection.2 5 6 15 16 During acute rejection,
high left atrial pressures combined with increased myocardial
stiffness can lead to a number of echocardiographic changes
such as early opening of the mitral valve (short isovolumetric
relaxation period); rapid filling of the left ventricle during the
passive filling phase in association with a rapid increase of left
ventricular pressure (high E and decreased deceleration time);
and subsequent small contribution of atrial contraction to left
ventricular filling (low A and increased E/A ratio).4 Although
some authors described an association between acute
rejection and echocardiographic variables at the group level,
the considerable overlap between individual patients still lim-
its replacement of EMB as the benchmark for diagnosis of
acute rejection after heart transplantation.
In the present study, no direct association was found at the
group level between the studied echocardiographic para-
meters and histological evidence of acute rejection alone. This
is in agreement with earlier findings and can be explained by
the influence of numerous factors. Besides the risk of false
negative biopsies and the effect of the immune response, left
ventricular filling properties and heart morphology can be
affected by loading conditions, hypertension, oedema result-
ing from ischaemia/reperfusion injury, and treatment with
diuretics or vasodilators.15–19 Moreover, it has been described
that treatment with cyclosporin, in comparison with previous
treatment strategies without calcineurin blockers, results in
less pronounced morphological and functional changes
during acute rejection with loss of sensitivity of echocardio-
graphic parameters.20 Furthermore, diastolic function param-
eters improve in the early postoperative period, reflecting
recovery from the operative insult, which may conceal acute
changes caused by the rejection process.4 Increased left
ventricular mass in the absence of histological signs of acute
rejection may also be the result of vascular (humoral)
rejection, in which the cells of the microvasculature are
targeted for injury early in the alloimmune response.7
However, because vascular rejection was not determined rou-
tinely in EMB, we were unable to evaluate the contribution of
vascular rejection (alone or in combination with cellular rejec-
tion) to left ventricular wall thickening in our patients.
IL-2 mRNA expression in relation to rejection
IL-2 is a key regulator of cellular immunity by its autocrine
stimulation of T cell maturation, differentiation, proliferation,
and apoptosis.10 21 In agreement with our previous results, we
found a strong relation between local IL-2 mRNA expression
in EMB and histological signs of acute rejection.11 However,
IL-2 mRNA is not always present during acute rejection and,
inversely, acute rejection is not always diagnosed during the
presence of IL-2 mRNA.14 22 Several factors may explain this
discrepancy. Firstly, as a result of sampling errors the diagno-
sis of acute rejection may be false negative. Secondly, because
of the redundancy of the cytokine network, lymphocyte
proliferation can be stimulated by alternative T cell growth
factors (such as IL-15) during inhibition of IL-2 mRNA
expression by immunosuppressive therapy.23 Thirdly, IL-2
mRNA expression may precede histological and clinical signs
of acute rejection or IL-2 mRNA can be expressed by a low
number of infiltrated lymphocytes in the absence of myocyte
damage (low grade rejection).24 Besides, although intragraft
cytokine measurements do not automatically reflect periph-
eral events, we cannot entirely exclude the influence of bacte-
rial or viral infection episodes on IL-2 mRNA expression
within the graft. Finally, high concentrations of local IL-2 may
trigger apoptosis of activated lymphocytes, thereby downregu-
lating the immune response.21
Diastolic function in relation to IL-2 mRNA expression
New onset left ventricular dysfunction after heart transplan-
tation may be caused by the presence and cytotoxic effects of
infiltrating immune cells, but may also depend on the produc-
tion of cytokines (such as IL-2) by these infiltrating cells.25
Cardiac complications are a common side effect of recom-
binant IL-2 immunotherapy in humans.13 Moreover, in the
transplant setting, high IL-2 serum concentrations have been
associated with impaired haemodynamics but were not corre-
lated with impaired diastolic graft function as detected by
echocardiography.26 Valantine and colleagues27 found no
relation between IL-2 mRNA expression in EMB and acute
rejection or allograft dysfunction. However, the measured IL-2
mRNA expression levels in their study were extremely low,
probably because of the in situ hybridisation technique that
they used.
In the present study, we found a significant relation
between IL-2 positive acute rejection and increased left
Table 4 Echocardiographic parameters at the time of EMB with (AR+) and without (AR−) acute rejection and with
(IL-2+) and without (IL-2−) IL-2 mRNA expression
AR−/IL-2− AR−/IL-2+ p Value AR+/IL-2− AR+/IL-2+ p Value
TWT( cm) 2.16 (0.30) 2.05 (0.30) 0.13 2.02 (0.14) 2.19 (0.31) 0.12
E (m/s) 0.82 (0.19) 0.84 (0.28) 0.66 0.71 (0.28) 0.87 (0.17) 0.13
E/A ratio 2.22 (0.73) 2.14 (0.63) 0.68 1.70 (0.54) 2.18 (0.86) 0.25
DET (ms) 161.5 (31.3) 175.2 (30.4) 0.11 143.3 (6.5) 156.1 (37.3) 0.32
IRP (ms) 64.69 (19.50) 65.22 (21.60) 0.92 64.64 (26.16) 74.17 (12.07) 0.37
Data are mean (SD).
A, peak atrial mitral flow velocity; DET, deceleration time of peak early mitral flow velocity; E, peak early mitral flow velocity; IRP,: isovolumetric relaxation
period; TWT, left ventricular total wall thickness.
Figure 1 Change in left ventricular total wall thickness (TWT) (%)
from the first postoperative measurement to the first acute rejection
(AR) in patients without (n = 3) and with (n = 6) interleukin 2 (IL-2)
messenger RNA expression during that first acute rejection (left) and
to the first IL-2 positive biopsy in control patients with no signs of
acute rejection episode (n = 4, right); p = 0.048, Fisher’s exact test.
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ventricular total wall thickness. This increase was not seen in
patients with IL-2 positive AR− EMB or in patients with IL-2
negative acute rejections. We speculate that the IL-2 expres-
sion during acute rejection in our patient group may reflect
the severity of the inflammation process during acute
rejection. We did not observe a similar association with the
measured functional parameters (E, A, deceleration time, and
isovolumetric relaxation period), probably because of the large
influence of loading conditions and blood pressure on these
parameters. Our previous finding that IL-2 mRNA expression
during the first acute rejection is associated with early devel-
opment of graft vascular disease supports the hypothesis that
IL-2 positive acute rejection episodes are more serious than
IL-2 negative acute rejections.14 Because vascular leakage is a
known side effect of IL-2 immunotherapy, it is likely that the
wall thickening seen during IL-2 positive rejection episodes is
the result of oedema.28 IL-2 may lead to oedema by stimulating
the production of inducible nitric oxide synthase, leading to
overproduction of nitric oxide, which has been reported to
cause capillary damage followed by fluid leakage.29
In summary, our results show a significant increase of left
ventricular total wall thickness before IL-2 positive acute
rejection. Whether vascular rejection plays a part in this proc-
ess remains to be determined. We conclude that rejection
accompanied by intragraft IL-2 mRNA expression has a
greater influence on heart morphology and therefore may be
indicative of more severe rejection.
. . . . . . . . . . . . . . . . . . . . .
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